Loading
A phase 1/2 trial of QL2107 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients is a phase 1/2 interventional study registered as NCT06911827 by Qilu Pharmaceutical Co., Ltd., with 149 participants planned, started 2025-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: QLP2117 and QL2107.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares QL2107, Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares QL2107, Qilu Pharmaceutical.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/